Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease: Reply

Archives of Internal Medicine

Volumn 168, Issue 6, 2008, Pages 667-668

  Sorrentino, Dario ^a   Terrosu, Giovanni ^b   Avellini, Claudio ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; METHOTREXATE;

CANCER RECURRENCE; CANCER RISK; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; GENETIC HETEROGENEITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; T CELL LYMPHOMA;

EID: 41549106281     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.6.667-a     Document Type: Letter

References (7)

1. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44(2):265-267.
2. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007;56(9):1181-1183.
3. Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med. 2007;167(16):1804-1807.
4. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut. 2006;55(2):228-233.
5. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433-1439.
6. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006;101(5):1030-1038.
7. Schröder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol. 2006;18(1):11-16.